Fig. 4

Prediction of ICB therapy resistance. A,B Patients in the EIC showed a relatively higher expression level of PD-L1 and higher TIDE prediction score for ICB therapy. C Metastatic melanoma patients with no response to anti-PD-1 therapy had higher enrichment scores of 167 exhausted immune classifier genes compared to patients with response. D The EIC showed higher enrichment score than the rest class in all tumour stage TCGA LUSC. E Box plot shows higher expression of TGFB1 in the EIC than rest class